{"id":37651,"date":"2025-07-21T15:42:46","date_gmt":"2025-07-21T07:42:46","guid":{"rendered":"https:\/\/flcube.com\/?p=37651"},"modified":"2025-07-21T15:42:46","modified_gmt":"2025-07-21T07:42:46","slug":"jumpcan-pharmaceuticals-jike-shu-approved-by-nmpa-for-influenza-a-and-b-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37651","title":{"rendered":"Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment"},"content":{"rendered":"\n

Shanghai-based Jumpcan Pharmaceutical (SHA: 600566<\/a>) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.<\/p>\n\n\n\n

Mechanism of Action<\/strong>
Jike Shu exerts its antiviral effects by specifically inhibiting the transcription of viral mRNA, thereby directly intervening in the core process of viral genome replication. This targeted mechanism enables the drug to effectively combat influenza viruses.<\/p>\n\n\n\n

Clinical Profile<\/strong>
Clinical trials have demonstrated that Jike Shu possesses long-lasting antiviral activity. With a long half-life and rapid onset of action, the drug can reduce fever within one day and alleviate all influenza symptoms within approximately 39.4 hours. Additionally, it has shown good safety and a low risk of drug interactions.<\/p>\n\n\n\n

Clinical Trials and Research<\/strong>
The Phase II\/III clinical trials of Jike Shu were led by Professor Zhang Wenhong. The results have been published in the journal Clinical Microbiology and Infection<\/em>. The clinical research was based entirely on data from the Chinese population, making it particularly suitable for the physiological characteristics of the Chinese people. Jike Shu was independently developed by Zenshine Pharmaceuticals, and Jumpcan acquired the exclusive promotion rights in Mainland China in August 2023.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike…<\/p>\n","protected":false},"author":1,"featured_media":37652,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2418,15,2419],"class_list":["post-37651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-jumpcan-pharmaceutical","tag-product-approvals","tag-sha-600566"],"yoast_head":"\nJumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37651\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37651\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-21T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment\",\"datePublished\":\"2025-07-21T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651\"},\"wordCount\":260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2108.webp\",\"keywords\":[\"Jumpcan Pharmaceutical\",\"Product approvals\",\"SHA: 600566\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37651#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37651\",\"name\":\"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2108.webp\",\"datePublished\":\"2025-07-21T07:42:46+00:00\",\"description\":\"Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37651\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2108.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2108.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37651#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment - Insight, China's Pharmaceutical Industry","description":"Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37651","og_locale":"en_US","og_type":"article","og_title":"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment","og_description":"Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.","og_url":"https:\/\/flcube.com\/?p=37651","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-21T07:42:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37651#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37651"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment","datePublished":"2025-07-21T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37651"},"wordCount":260,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp","keywords":["Jumpcan Pharmaceutical","Product approvals","SHA: 600566"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37651#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37651","url":"https:\/\/flcube.com\/?p=37651","name":"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37651#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp","datePublished":"2025-07-21T07:42:46+00:00","description":"Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37651#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37651"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37651#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp","width":1080,"height":608,"caption":"Jumpcan Pharmaceutical's Jike Shu Approved by NMPA for Influenza A and B Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37651#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2108.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37651"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37651\/revisions"}],"predecessor-version":[{"id":37653,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37651\/revisions\/37653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37652"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}